UniSA Ventures

UniSA Ventures is the technology commercialisation and investment management company of the University of South Australia (UniSA). Founded in 1991, the firm is dedicated to translating the university's world-class research into real-world commercial outcomes, with a strong focus on healthcare, biotechnology, and life sciences. UniSA Ventures manages a diverse portfolio of intellectual property, facilitates licensing agreements, and supports the creation of spin-out companies by providing seed capital and corporate governance. Notable spin-outs and investee companies include Ferronova, AbRegen, and Carina Biotech, which develop advanced cancer diagnostics, antibody-based wound healing therapeutics, and CAR-T cell therapies, respectively. The company also manages strategic initiatives like the Adelaide China Biotech Investment Fund to bridge the gap between early-stage research and clinical development.